PubMed Health treatment related to Lymphangioleiomyomatosis: 63
Currently, no treatment is available to stop the growth of the cysts and cell clusters that occur in LAM. Most treatments for LAM are aimed at easing symptoms and preventing complications. The main treatments are: Medicines to improve air flow in the lungs and reduce wheezing Oxygen therapy Procedures to remove fluid from the chest or abdomen and stop it from building up again Procedures to shrink angiomyolipomas (AMLs) Lung transplant Hormone therapy
Drugs for Lymphangioleiomyomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 87)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 4 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
2 |
|
Antiprotozoal Agents |
|
Phase 4 |
|
|
|
3 |
|
Antiparasitic Agents |
|
Phase 4 |
|
|
|
4 |
|
Antimalarials |
|
Phase 4 |
|
|
|
5 |
|
Simvastatin |
Approved |
Phase 1, Phase 2 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
6 |
|
Nintedanib |
Approved |
Phase 2 |
|
656247-17-5 |
135423438 9809715 |
Synonyms:
BIBF 1120
BIBF1120
BIBF-1120
BIBF-1120|BIBF1120|Ofev®|Vargatef®
INTEDANIB
|
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
NINTEDANIB
Nintedanib esylate
Ofev
Vargatef
|
|
7 |
|
Somatostatin |
Approved, Investigational |
Phase 2 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
8 |
|
Octreotide |
Approved, Investigational |
Phase 2 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
9 |
|
Letrozole |
Approved, Investigational |
Phase 2 |
|
112809-51-5 |
3902 |
Synonyms:
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
CGS-20267
FEM345
Femara
Fémara
|
Femara®
Letrozol
LETROZOLE
Novartis brand OF letrozole
|
|
10 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
11 |
|
Loratadine |
Approved, Investigational |
Phase 2 |
|
79794-75-5 |
3957 |
Synonyms:
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester
Alavert
Amantadine
Anhissen
Bonalerg
CHILDREN'S CLARITIN
Claritin
CLARITIN HIVES RELIEF
CLARITIN HIVES RELIEF REDITAB
CLARITIN REDITABS
Claritin®|SCH-29851
CLARITIN-D
Claritine
Clarityn
CLARITYN RAPIDE
Clarityne
Clarium
Cronopen
Flonidan
|
Fristamin
HAY-RITE
Histaloran
Klaritin
Lertamine
Lisino
Loracert
Loradex
Loranox
Lorastine
Loratadina
Loratadine
LORATADINE REDIDOSE
Loratadine wyeth brand
Loratadinum
Loratidine
ROLETRA
SCH-29851
Wyeth brand OF loratadine
|
|
12 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
13 |
|
Salbutamol |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
18559-94-9 |
2083 |
Synonyms:
(±)-SALBUTAMOL
(L)-Albuterol
1-(Tert-butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol
2-(Tert-butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol
2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol
4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol
ACCUNEB
Aerolin
AEROLIN 400
AEROLIN AUTO
AIROMIR
AIRSALB
Albuterol
Albuterol sulfate
Albuterol Sulphate
albuterol|SCH-13949W|Ventolin®
Almotex
Alpha'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
Alti-salbutamol
Anebron
Arubendol-salbutamol
Asmadil
Asmanil
Asmasal
ASMASAL CLICKHALER
ASMASAL SPACEHALER
Asmatol
Asmaven
ASMAVENT
Asmidon
Asmol
Asmol uni-dose
Asthalin
Asthavent
Broncho-spray
Broncovaleas
Bronter
BTA204
Bugonol
Bumol
Butamol
Buto-asma
Butohaler
Butotal
Butovent
Buventol
Cetsim
Cobutolin
COMBIVENT
COMBIVENT UDVS
Dilatamol
DL-Albuterol
DL-N-Tert-butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine
DL-Salbutamol
DUONEB
Ecovent
Farcolin
Gerivent
Grafalin
IPRAMOL STERI-NEB
KENTAMOL
Levalbuterol
LIBETIST
Libretin
Loftan
MAXIVENT
Medolin
Mozal
Novosalmol
Parasma
Pneumolat
ProAir
PROAIR HFA
Proventil
|
Proventil hfa
Proventil inhaler
PROVENTIL-HFA
Respax
Respolin
RIMASAL
Rotahaler
R-Salbutamol
Sabutal
Salamol
SALAMOL E-BREATHE
SALAPIN
Salbetol
Salbron
Salbu-basf
Salbu-fatol
Salbuhexal
Salbulin
SALBULIN NOVOLIZER
Salbupur
Salbusian
Salbutalan
SALBUTAMOL
Salbutamol free base
Salbutamol sulfate
Salbutamol sulphate
Salbutamolum
Salbutan
Salbutard
Salbutine
Salbutol
Salbuven
Salbuvent
SALIPRANEB
Sallbupp
Salmaplon
Salomol
Salvent
Saventol
SCH 13949W
SCH-13949W
Servitamol
Solbutamol
Spreor
STERI-NEB SALAMOL
Sultanol
Sultanol N
Suprasma
Suxar
Theosal
Tobybron
Vencronyl
Venetlin
Ventalin Inhaler
Ventamol
Ventilan
Ventiloboi
VENTMAX SR
Ventodisks
Ventolin
VENTOLIN CR
VENTOLIN E-BREATHE
VENTOLIN HFA
Ventolin inhaler
Ventolin rotacaps
Ventoline
Volare albuterol hfa
Volare easi-breathe
Volma
Volmax
Xopenex
Xopenex HFA
Zaperin
|
|
14 |
|
Resveratrol |
Investigational |
Phase 2 |
|
501-36-0 |
445154 |
Synonyms:
(E)-2-(3,5-Dihydroxyphenyl)-1-(4-hydroxyphenyl)ethene
(E)-3,4',5-Trihydroxystilbene
(E)-3,4’,5-Trihydroxystilbene
(e)-5-(2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(e)-Resveratrol
3,4',5-Stilbenetriol
3,4',5-stilbenetriol|3,5,4'-trihydroxystilbene|trans-resveratrol
3,4',5-Trihydroxystilbene
3,4',5-Trihydroxy-trans-stilbene
3,4’,5-Stilbenetriol
3,4’,5-Trihydroxystilbene
3,4’,5-Trihydroxy-trans-stilbene
|
3,5,4'-Trihydroxystilbene
3,5,4'-TRIHYDROXY-TRANS-STILBENE
5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
5-[(e)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diol
BIA 6-512
BIA-6-512
NSC-327430
Resveratrol
SRT 501
SRT-501
trans Resveratrol
trans-3,4',5 - Trihydroxystilbene
trans-3,5,4’-Trihydroxystilbene
trans-3,5,4'-Trihydroxystilbene
trans-Resveratrol
|
|
15 |
|
Saracatinib |
Investigational |
Phase 2 |
|
379231-04-6 |
10302451 |
Synonyms:
AZ-10353926
AZD 0530
AZD0530
AZD-0530
AZD0530 difumarate
AZD-0530|AZD0530
N-(5-chloro-1,3-Benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-((tetrahydro- 2H-pyran-4-yl)oxy)quinazolin-4-amine bi((2E)-but-2-enedioate)
|
N-(5-chloro-1,3-Benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
N-(5-Chloro-2H-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine
SARACATINIB
Saracatinib difumerate
Saracatinibum
|
|
16 |
|
Anticholesteremic Agents |
|
Phase 1, Phase 2 |
|
|
|
17 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
19 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
20 |
|
Estrogens |
|
Phase 2 |
|
|
|
21 |
|
Estrogen Receptor Antagonists |
|
Phase 2 |
|
|
|
22 |
|
Estrogen Antagonists |
|
Phase 2 |
|
|
|
23 |
|
Hormones |
|
Phase 2 |
|
|
|
24 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
25 |
|
Aromatase Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
27 |
|
Analgesics |
|
Phase 2 |
|
|
|
28 |
|
Cyclooxygenase Inhibitors |
|
Phase 2 |
|
|
|
29 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 2 |
|
|
|
30 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
31 |
|
Cola |
|
Phase 2 |
|
|
|
32 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
33 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
34 |
|
Imatinib Mesylate |
|
Phase 1, Phase 2 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
35 |
|
Anti-Allergic Agents |
|
Phase 2 |
|
|
|
36 |
|
Histamine phosphate |
|
Phase 2 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
37 |
|
Histamine H1 Antagonists, Non-Sedating |
|
Phase 2 |
|
|
|
38 |
|
Histamine H1 Antagonists |
|
Phase 2 |
|
|
|
39 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
40 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
41 |
|
Bronchodilator Agents |
|
Phase 1, Phase 2 |
|
|
|
42 |
|
Adrenergic beta-Agonists |
|
Phase 1, Phase 2 |
|
|
|
43 |
|
Adrenergic Agonists |
|
Phase 1, Phase 2 |
|
|
|
44 |
|
Anti-Asthmatic Agents |
|
Phase 1, Phase 2 |
|
|
|
45 |
|
Adrenergic Agents |
|
Phase 1, Phase 2 |
|
|
|
46 |
|
Respiratory System Agents |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Tocolytic Agents |
|
Phase 1, Phase 2 |
|
|
|
48 |
|
Platelet Aggregation Inhibitors |
|
Phase 2 |
|
|
|
49 |
|
Antioxidants |
|
Phase 2 |
|
|
|
50 |
|
Protective Agents |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 44)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis. |
Completed |
NCT00989742 |
Phase 4 |
Doxycycline;Placebo |
2 |
Lymphangioleiomyomatosis Efficacy and Safety Trial |
Unknown status |
NCT00414648 |
Phase 3 |
Sirolimus;Placebo sirolimus |
3 |
A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) |
Completed |
NCT00790400 |
Phase 3 |
Everolimus (RAD001);Everolimus Placebo |
4 |
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial |
Recruiting |
NCT03150914 |
Phase 3 |
Sirolimus |
5 |
A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis |
Unknown status |
NCT00490789 |
Phase 2 |
sirolimus |
6 |
Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis |
Completed |
NCT00457808 |
Phase 2 |
Rapamycin, sirolimus |
7 |
RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis |
Completed |
NCT00457964 |
Phase 1, Phase 2 |
RAD001 |
8 |
The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC) |
Completed |
NCT02061397 |
Phase 1, Phase 2 |
Simvastatin;Sirolimus Oral Product;Everolimus Oral Product |
9 |
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis |
Completed |
NCT00792766 |
Phase 1, Phase 2 |
everolimus (RAD001) |
10 |
A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM) |
Completed |
NCT03062943 |
Phase 2 |
Nintedanib |
11 |
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis |
Completed |
NCT00005906 |
Phase 2 |
Octreotide |
12 |
An Exploratory, Open-label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis |
Completed |
NCT01059318 |
Phase 2 |
Everolimus |
13 |
A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS |
Completed |
NCT01353209 |
Phase 2 |
Letrozole;Placebo |
14 |
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC |
Completed |
NCT02484664 |
Phase 2 |
Celecoxib |
15 |
LAM Pilot Study With Imatinib Mesylate |
Completed |
NCT03131999 |
Phase 1, Phase 2 |
Imatinib Mesylate 400Mg Capsule;Placebo - Capsule |
16 |
Phase II Clinical Trial Evaluating the Effect of Loratadine Associated to Rapamicyn in Patients With Lymphangioleiomyomatosis |
Recruiting |
NCT05190627 |
Phase 2 |
Loratadine;Placebo 10mg/day added to rapamycin for 12 months |
17 |
Feasibility Study of [11C]Acetate Positron Emission Tomography (PET) as an Indicator of Early Response to Rapamycin in Lymphangioleiomyomatosis (LAM) Patients |
Recruiting |
NCT05467397 |
Phase 1, Phase 2 |
[11C]acetate |
18 |
Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis |
Recruiting |
NCT01799538 |
Phase 1, Phase 2 |
albuterol inhaler;albuterol nebulizer |
19 |
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT) |
Active, not recruiting |
NCT03253913 |
Phase 2 |
Sirolimus;Resveratrol |
20 |
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis |
Terminated |
NCT02737202 |
Phase 2 |
saracatinib |
21 |
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) |
Completed |
NCT02116712 |
Phase 1 |
Saracatinib |
22 |
Glutamine PET Imaging in LAM |
Completed |
NCT04388371 |
Phase 1 |
Glutamine |
23 |
Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus |
Completed |
NCT01687179 |
Phase 1 |
"Sirolimus" and "Hydroxychloroquine" 200 mg;"Sirolimus" and "Hydroxychloroquine" 400 mg |
24 |
Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc. |
Recruiting |
NCT04273334 |
Phase 1 |
68Ga-NEB |
25 |
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications |
Active, not recruiting |
NCT01552434 |
Phase 1 |
Temsirolimus;Valproic Acid |
26 |
Effect of Fasting on the Size of Lymphangioleiomyomas in Patients With Lymphangioleiomyomatosis |
Completed |
NCT00552955 |
|
|
27 |
Evaluation of the Impact of a Pulmonary Rehabilitation Program on Exercise Capacity in Patients With Lymphangioleiomyomatosis |
Completed |
NCT02009241 |
|
|
28 |
Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM) - a Retrospective Analysis |
Completed |
NCT04184193 |
|
|
29 |
Observational Study of Patients With Lymphangioleiomyomatosis and Pulmonary Hypertension |
Completed |
NCT00960895 |
|
|
30 |
Lymphangioleiomyomatosis (LAM) Registry |
Completed |
NCT00005486 |
|
|
31 |
Lymphangioleiomyomatosis (LAM) Registry |
Completed |
NCT00001869 |
|
|
32 |
Clinical Profile Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Followed at Hospital Das Clínicas, University of Sao Paulo Medical School |
Completed |
NCT02325505 |
|
|
33 |
Role of Helicobacter Pylori and Its Toxins in Pulmonary and Oropharyngeal Disease |
Completed |
NCT00366509 |
|
|
34 |
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients |
Completed |
NCT02859194 |
|
|
35 |
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM) |
Recruiting |
NCT00001465 |
|
|
36 |
A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Lymphangioleiomyomatosis (LAM-CHINA) |
Recruiting |
NCT03193892 |
|
|
37 |
Study of New Potential Biomarkers of Lymphangioleiomyomatosis: Determination of Cathepsin K, Cystatin C, Collagen Telopeptides and Chondroitin Sulfates |
Recruiting |
NCT05323370 |
|
|
38 |
National Lymphangioleiomyomatosis Registry, France |
Recruiting |
NCT01484236 |
|
|
39 |
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis |
Recruiting |
NCT04577937 |
|
|
40 |
Discovery of Sirolimus Sensitive Biomarkers in Blood |
Recruiting |
NCT03304678 |
|
|
41 |
Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS) |
Recruiting |
NCT02432560 |
|
Sirolimus;Everolimus |
42 |
Lymphatic Anomalies Registry for the Assessment of Outcome Data |
Recruiting |
NCT02399527 |
|
|
43 |
Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol |
Active, not recruiting |
NCT02654340 |
|
|
44 |
Characterizing Lymphangioleiomyomatosis (LAM) With 11C-Choline PET/CT |
Not yet recruiting |
NCT05087134 |
Early Phase 1 |
11C-Choline |
|